Curis, Inc. (CRIS) Lowered to “Sell” at ValuEngine
Curis, Inc. (NASDAQ:CRIS) was downgraded by equities researchers at ValuEngine from a “hold” rating to a “sell” rating in a research note issued to investors on Friday.
Several other equities analysts have also weighed in on CRIS. Zacks Investment Research raised Curis from a “sell” rating to a “hold” rating in a report on Monday, July 17th. BidaskClub lowered Curis from a “hold” rating to a “sell” rating in a report on Thursday, July 27th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. Curis currently has an average rating of “Hold” and an average price target of $5.50.
Curis (NASDAQ:CRIS) traded down 6.52% during mid-day trading on Friday, reaching $1.72. The company had a trading volume of 1,455,935 shares. The stock has a 50-day moving average of $1.82 and a 200 day moving average of $2.13. Curis has a 12-month low of $1.47 and a 12-month high of $3.72. The company’s market capitalization is $247.47 million.
Curis (NASDAQ:CRIS) last announced its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.01). Curis had a negative net margin of 836.18% and a negative return on equity of 236.43%. The firm had revenue of $2.10 million for the quarter, compared to the consensus estimate of $2.08 million. During the same period last year, the company posted ($0.09) earnings per share. Curis’s revenue for the quarter was up 23.5% on a year-over-year basis. On average, analysts expect that Curis will post ($0.40) EPS for the current year.
ILLEGAL ACTIVITY WARNING: “Curis, Inc. (CRIS) Lowered to “Sell” at ValuEngine” was originally published by American Banking News and is the property of of American Banking News. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/09/16/curis-inc-cris-lowered-to-sell-at-valuengine.html.
Several institutional investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. boosted its holdings in shares of Curis by 1.6% in the second quarter. Goldman Sachs Group Inc. now owns 119,638 shares of the biotechnology company’s stock worth $226,000 after acquiring an additional 1,880 shares during the period. Rhumbline Advisers boosted its holdings in shares of Curis by 1.9% in the second quarter. Rhumbline Advisers now owns 127,529 shares of the biotechnology company’s stock worth $241,000 after acquiring an additional 2,340 shares during the period. American International Group Inc. boosted its holdings in shares of Curis by 7.1% in the first quarter. American International Group Inc. now owns 68,733 shares of the biotechnology company’s stock worth $191,000 after acquiring an additional 4,560 shares during the period. Weiss Multi Strategy Advisers LLC boosted its holdings in shares of Curis by 4.8% in the first quarter. Weiss Multi Strategy Advisers LLC now owns 130,000 shares of the biotechnology company’s stock worth $361,000 after acquiring an additional 6,000 shares during the period. Finally, Dynamic Technology Lab Private Ltd boosted its holdings in shares of Curis by 22.3% in the first quarter. Dynamic Technology Lab Private Ltd now owns 41,922 shares of the biotechnology company’s stock worth $117,000 after acquiring an additional 7,638 shares during the period. 50.94% of the stock is owned by hedge funds and other institutional investors.
Curis Company Profile
Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.